Evaluation of anti-lived and anti-fixed Leishmania (Viannia) braziliensis promastigote IgG antibodies detected by flow cytometry for diagnosis and post-therapeutic cure assessment in localized cutaneous leishmaniasis

Diagn Microbiol Infect Dis. 2012 Nov;74(3):292-8. doi: 10.1016/j.diagmicrobio.2012.06.025. Epub 2012 Sep 21.

Abstract

This study aims to investigate a flow cytometry performance-based methodology to detect anti-live (FC-ALPA-IgG) and anti-fixed (FC-AFPA-IgG) Leishmania (Viannia) braziliensis promastigote IgG as a means to monitor post-therapeutic cure of patients with localized cutaneous leishmaniasis (LCL). Serum samples from 30 LCL patients infected with L. (V.) braziliensis were assayed, comparing the IgG reactivity before and after specific treatment with pentavalent antimonial. Reactivities were reported as the percentage of positive fluorescent parasites (PPFP), using a PPFP of 60% as a cut-off value. In the serum dilution of 1:1024, the positive percentage of LCL serum sample for FC-ALPA-IgG and FC-AFPA-IgG was 86% and 90%, respectively, before treatment. Analysis of ∆PPFP that represents the difference between PPFP after and before treatment appeared as a new approach to monitor post-therapeutic IgG reactivity in LCL. Our data support the perspective of using FC-ALPA and FC-AFPA as a useful serologic tool for diagnosis and for post-therapeutic follow-up of LCL patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Protozoan / blood*
  • Antiprotozoal Agents / administration & dosage
  • Drug Monitoring / methods*
  • Female
  • Flow Cytometry / methods*
  • Humans
  • Immunoglobulin G / blood*
  • Leishmania braziliensis / immunology*
  • Leishmaniasis, Cutaneous / diagnosis*
  • Leishmaniasis, Cutaneous / drug therapy*
  • Leishmaniasis, Cutaneous / immunology
  • Male
  • Middle Aged
  • Treatment Outcome
  • Young Adult

Substances

  • Antibodies, Protozoan
  • Antiprotozoal Agents
  • Immunoglobulin G